CLEVELAND— Great Lakes Brewing Co. (GLBC) joins brewers across the country in the Ales for ALS campaign. Ales for ALS is a national program that unites some of America’s top craft brewers in support of the work at the ALS Therapy Development Institute (ALS TDI) to end ALS.
Ales for ALS participants receive a special blend of experimental hops provided by Loftus Ranches and Hopunion. Participating brewers will brew special beers with these hops and donate a portion of the sales to ALS TDI, a nonprofit biotech in Cambridge, MA that is focused solely on developing treatments and a cure for ALS, also known as Lou Gehrig’s disease.
As part of this program, GLBC brewers have created a heavily hopped White IPA brewed with GLBC’s Belgian witbier yeast and spiced with coriander, white pepper, and lemongrass. The beer will be tapped on Friday, July 12 at 4PM and sold exclusively in the GLBC Brewpub while supplies last. GLBC will donate $1 from each White IPA pint sold to ALS TDI.
For more information about Ales for ALS, please visit alesforals.com.
Amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease) is a progressive neurodegenerative disease that leads to paralysis due to the death of motor neurons in the spinal cord and brain. There is no known cure for the disease. About 5,000 people in the US are diagnosed with ALS each year. With no effective treatment, the average patient survives only 2-5 years following diagnosis. There are about 30,000 people in the US diagnosed with ALS today.
About ALS Therapy Development Institute:
The mission of the ALS Therapy Development Institute (ALS TDI) is to develop effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease) as soon as possible for patients today. Focused on fulfilling this urgent, unmet medical need, ALS TDI executes a robust target discovery program while simultaneously operating the world’s largest efforts to preclinically validate potential therapeutics, including a pipeline of dozens of small molecules, protein biologics, gene therapies and cell-based constructs. The world’s first nonprofit biotech institute, ALS TDI has developed an industrial-scale platform, employs 30 professional scientists and evaluates dozens of potential therapeutics each year. Built by and for patients, the Cambridge,
Massachusetts-based research institute collaborates with leaders in both academia and industry to accelerate ALS therapeutic development, including Biogen Idec, UCB, Aestus Therapeutics, MDA and RGK Foundation. For more information, please visit us online at www.als.net.